Glenmark Pharmaceuticals has started manufacturing samples at its new plant in Indore. These samples will be shipped for the approval of the US Food and Drug Authority (USFDA) before it can launch the products at the world’s largest drug market. The company has invested 80-100 crore in the plant that has initial capacity to manufacture a million tablets per year solely for exports to US and the UK. Glenmark is hoping to get USFDA approval for the plant within a year, which will be crucial for its revenue growth from 2012 as the firm estimates it will run out of capacity in its existing manufacturing units within a year or so.crackcrack
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.25 |
| Dr. Reddys Lab | 1220.75 |
| Cipla | 1232.90 |
| Zydus Lifesciences | 928.85 |
| Lupin | 2311.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: